VRTX logo

VRTX

Profile

Full Name

Vertex Pharmaceuticals Incorporated

Ticker Symbol

VRTX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

July 24, 1991

Indexes

S&P 500,NASDAQ 100

Website

http://www.vrtx.com

Employees

6100

Key Details

Price

$492.47(+0.01%)

Market cap

$126.46B(Mega cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$11.02B(+11.66% YoY)

Annual EPS

-$2.08(-114.97% YoY)

PE ratio

-

Next earnings date

May 5, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$492.47
VRTX price is $492.47

30-Day Relative Volume

0.85
VRTX 30-day relative volume is 0.85

Price Performance

Price Today change

+0.01%
VRTX price is up +0.01% today

Price YTD change

+22.29%
VRTX price is up +22.29% since January 1st

Price 1-year change

+22.88%
VRTX price is up +22.88% year-on-year

Price 3-year change

+82.11%
VRTX price is up +82.11% over the past 3 years

Price Range

Price All-time high

$519.88
VRTX price is currently -5.27% below its historical high of $519.88

Price 3-year low

$233.01
VRTX price is currently +111.35% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$126.46B
VRTX market capitalization is $126.46 billion

Market cap 3-year change

+82.98%
VRTX market capitalization is up +82.98% over the past 3 years

Market cap All-time high

$133.92B
VRTX market capitalization is currently -5.57% below its historical high of $133.92 billion

Market cap sector rank

98.51%
VRTX market capitalization is higher than 98.51% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-0.58%
VRTX shares outstanding is down -0.58% year-on-year

Shares Outstanding 3-Year Change

+0.48%
VRTX shares outstanding is up +0.48% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.40
VRTX beta is 0.40

200-day SMA

$471.19
VRTX price is currently +4.52% above its 200-day simple moving average

50-day SMA

$487.76
VRTX price is currently +0.96% above its 50-day simple moving average

RSI

52.79
VRTX 14-day relative strength index is 52.79

Volume

0.85
VRTX 30-day relative volume is 0.85

ATR

$13.97
VRTX average true range is $13.97

10-day Historical Volatility

30.67%
VRTX 10-day historical volatility is 30.67%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$11.02B
VRTX annual revenue is $11.02 billion

Revenue Analysts estimate

$11.97B
VRTX annual revenue is currently -7.95% lower than the consensus analysts' forecast

Revenue 1-year change

+11.66%
VRTX annual revenue is up +11.66% year-on-year

Revenue Sector rank

94.54%
VRTX annual revenue is higher than 94.54% of companies in Healthcare sector

EPS

EPS

-$2.08
VRTX annual earnings per share is -$2.08

EPS Analysts estimate

$17.96
VRTX annual earnings per share is currently -111.58% lower than the consensus analysts' forecast

EPS 1-year change

-114.97%
VRTX annual earnings per share is down -114.97% year-on-year

EPS Sector rank

37.65%
VRTX annual earnings per share is higher than 37.65% of companies in Healthcare sector

Profit

Gross profit

$9.49B
VRTX annual gross profit is $9.49 billion

Gross margin

86.11%
VRTX annual gross profit margin is 86.11%

Operating profit

$4.39B
VRTX annual operating income is $4.39 billion

Operating margin

39.88%
VRTX annual operating profit margin is 39.88%

Net income

-$535.60M
VRTX annual net profit is -$535.60 million

Net margin

-4.86%
VRTX annual net profit margin is -4.86%

Expenses

Total expenses

$6.63B
VRTX annual total expenses is $6.63 billion

Operating expenses

$5.09B
VRTX annual total operating expenses is $5.09 billion

Cost of goods sold

$1.53B
VRTX annual cost of goods sold is $1.53 billion

Selling, general & administrative expenses

$1.46B
VRTX annual SGA is $1.46 billion

Depreciation and amortization

$207.20M
VRTX annual depreciation & amortization is $207.20 million

Interest expense

$30.60M
VRTX annual interest expense is $30.60 million

Income tax

$784.10M
VRTX annual income tax is $784.10 million

EBIT & EBITDA

EBIT

$279.10M
VRTX annual earnings before interest & taxes is $279.10 million

EBITDA

$486.30M
VRTX annual EBITDA is $486.30 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$22.53B
VRTX annual total assets is $22.53 billion

Non current assets

$12.94B
VRTX annual long term assets is $12.94 billion

Current assets

$9.60B
VRTX annual total current assets is $9.60 billion

Cash and cash equivalents

$4.57B
VRTX annual cash & cash equivalents is $4.57 billion

Accounts receivable

$1.61B
VRTX annual accounts receivable is $1.61 billion

Inventory

$1.21B
VRTX annual inventory is $1.21 billion

Liabilities

Total liabilities

$6.12B
VRTX annual total liabilities is $6.12 billion

Long term liabilities

$2.56B
VRTX annual total long term liabilities is $2.56 billion

Current liabilities

$3.56B
VRTX annual total current liabilities is $3.56 billion

Accounts payable

$413.00M
VRTX annual accounts payable is $413.00 million

Debt

Total debt

$1.75B
VRTX annual total debt is $1.75 billion

Total debt 1-year change

+116.42%
VRTX annual total debt is up +116.42% year-on-year

Long term debt

$1.66B
VRTX annual long term debt is $1.66 billion

Short term debt

$92.30M
VRTX annual short term debt is $92.30 million

Equity & Capital

Shareholders equity

$16.41B
VRTX annual stockholders equity is $16.41 billion

Book value

$16.41B
VRTX annual book value is $16.41 billion

Retained earnings

$9.61B
VRTX annual retained earnings is $9.61 billion

Working capital

$6.03B
VRTX annual working capital is $6.03 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$492.60M
VRTX annual cash flow from operations is -$492.60 million

Cash from operations 1-year change

-113.93%
VRTX annual cash flow from operations is down -113.93% year-on-year

Cash from investing

-$3.77B
VRTX annual cash flow from investing activities is -$3.77 billion

Cash from investing 1-year change

-20%
VRTX annual cash flow from investing activities is down -20% year-on-year

Cash from financing

-$1.49B
VRTX annual cash flow from financing activities is -$1.49 billion

Cash from financing 1-year change

-165.9%
VRTX annual cash flow from financing activities is down -165.9% year-on-year

CAPEX

CAPEX

$485.40M
VRTX annual capital expenditures is $485.40 million

CAPEX 1-year change

+87.85%
VRTX annual capital expenditures is up +87.85% year-on-year

Free Cash Flow

Free cash flow

-$978.00M
VRTX annual free cash flow is -$978.00 million

Free cash flow 1-year change

-129.83%
VRTX annual free cash flow is down -129.83% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

86.11%
VRTX annual gross profit margin is 86.11%

Operating margin

39.88%
VRTX annual operating profit margin is 39.88%

Net margin

-4.86%
VRTX annual net profit margin is -4.86%

ROA & ROE

ROA

-2.37%
VRTX annual return on assets is -2.37%

ROE

-3.15%
VRTX annual return on equity is -3.15%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
VRTX price to earnings ratio value is unknown

PE ratio Sector rank

-
VRTX price to earnings ratio is unknown

PB Ratio

PB ratio

7.71
VRTX price to book ratio is 7.71

PB ratio Sector rank

89.13%
VRTX price to book ratio is higher than 89.13% of companies in Healthcare sector

PS Ratio

PS ratio

11.48
VRTX price to sales ratio is 11.48

PS ratio Sector rank

79.61%
VRTX price to sales ratio is higher than 79.61% of companies in Healthcare sector

Enterprise value

Enterprise value

$123.64B
VRTX enterprise value is $123.64 billion

Enterprise value Sector rank

98.42%
VRTX enterprise value is higher than 98.42% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

254.25
VRTX EV/EBITDA is 254.25

EV/EBITDA Sector rank

99.56%
VRTX EV/EBITDA is higher than 99.56% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.69
VRTX annual current ratio is 2.69

Quick ratio

2.35
VRTX annual quick ratio is 2.35

Leverage

Debt to equity

0.00
VRTX annual debt to equity ratio is 0.00

Interest coverage ratio

9.12
VRTX annual interest coverage ratio is 9.12

Risk & Stability

Piotroski F-Score

4
VRTX piotroski f-score is 4

Altman Z-Score

13.84
VRTX altman z-score is 13.84

Analyst ratings

Recent major analysts updates

Apr 1, 25 RBC Capital
Sector Perform
Mar 31, 25 B of A Securities
Buy
Feb 20, 25 RBC Capital
Sector Perform
Feb 12, 25 Canaccord Genuity
Hold
Feb 11, 25 Truist Securities
Buy
Feb 11, 25 Scotiabank
Sector Perform
Feb 11, 25 RBC Capital
Sector Perform
Feb 11, 25 Needham
Hold
Feb 11, 25 Morgan Stanley
Equal-Weight
Feb 11, 25 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

PFE logo
Pfizer (PFE)
GILD logo
Gilead Sciences (GILD)
SNY logo
Sanofi (SNY)
SYK logo
Stryker (SYK)
DHR logo
Danaher (DHR)
MDT logo
Medtronic (MDT)
BSX logo
Boston Scientific (BSX)
AMGN logo
Amgen (AMGN)
BMY logo
Bristol-Myers Squibb (BMY)
  • What is the ticker symbol for Vertex Pharmaceuticals Incorporated?
  • Does Vertex Pharmaceuticals Incorporated pay dividends?
  • What sector is Vertex Pharmaceuticals Incorporated in?
  • What industry is Vertex Pharmaceuticals Incorporated in?
  • What country is Vertex Pharmaceuticals Incorporated based in?
  • When did Vertex Pharmaceuticals Incorporated go public?
  • Is Vertex Pharmaceuticals Incorporated in the S&P 500?
  • Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?
  • Is Vertex Pharmaceuticals Incorporated in the Dow Jones?
  • When was Vertex Pharmaceuticals Incorporated's last earnings report?
  • When does Vertex Pharmaceuticals Incorporated report earnings?
  • Should I buy Vertex Pharmaceuticals Incorporated stock now?

What is the ticker symbol for Vertex Pharmaceuticals Incorporated?

The ticker symbol for Vertex Pharmaceuticals Incorporated is NASDAQ:VRTX

Does Vertex Pharmaceuticals Incorporated pay dividends?

No, Vertex Pharmaceuticals Incorporated does not pay dividends

What sector is Vertex Pharmaceuticals Incorporated in?

Vertex Pharmaceuticals Incorporated is in the Healthcare sector

What industry is Vertex Pharmaceuticals Incorporated in?

Vertex Pharmaceuticals Incorporated is in the Biotechnology industry

What country is Vertex Pharmaceuticals Incorporated based in?

Vertex Pharmaceuticals Incorporated is headquartered in United States

When did Vertex Pharmaceuticals Incorporated go public?

Vertex Pharmaceuticals Incorporated's initial public offering (IPO) was on July 24, 1991

Is Vertex Pharmaceuticals Incorporated in the S&P 500?

Yes, Vertex Pharmaceuticals Incorporated is included in the S&P 500 index

Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?

Yes, Vertex Pharmaceuticals Incorporated is included in the NASDAQ 100 index

Is Vertex Pharmaceuticals Incorporated in the Dow Jones?

No, Vertex Pharmaceuticals Incorporated is not included in the Dow Jones index

When was Vertex Pharmaceuticals Incorporated's last earnings report?

Vertex Pharmaceuticals Incorporated's most recent earnings report was on Feb 10, 2025

When does Vertex Pharmaceuticals Incorporated report earnings?

The next expected earnings date for Vertex Pharmaceuticals Incorporated is May 5, 2025

Should I buy Vertex Pharmaceuticals Incorporated stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page